Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types

Continued progress of lead program, AKTX-101, for the treatment of solid tumors

Read more at globenewswire.com